Results 31 to 40 of about 54,594 (319)

Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors

Pharmaceutics, 2022
Advancement in sequencing technologies allows for the identification of molecular pathways involved in tumor progression and treatment resistance.
Luigi Liguori, Giovanna Polcaro, Annunziata Nigro, Valeria Conti, Carmine Sellitto, Francesco Perri, Alessandro Ottaiano, Marco Cascella, Pio Zeppa, Alessandro Caputo, Stefano Pepe, Francesco Sabbatino   +11 more
doaj   +1 more source

Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns and opportunities.

Blood, 2022
Treatment paradigms for B-cell non-Hodgkin lymphomas (B-NHL) have shifted dramatically in the last two decades following the introduction of highly active immunotherapies, such as rituximab.
L. Falchi, S. Vardhana, G. Salles
semanticscholar   +1 more source

Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy

Cancer Biology and Medicine, 2023
Advances in antibody engineering have led to the generation of more innovative antibody drugs, such as bispecific antibodies (bsAbs). Following the success associated with blinatumomab, bsAbs have attracted enormous interest in the field of cancer ...
Tiancheng Zhang, Youpei Lin, Qiang Gao
semanticscholar   +1 more source

Perspective: Designing T-Cell Engagers With Better Therapeutic Windows

Frontiers in Oncology, 2020
This perspective highlights the history and challenges of developing CD3-based bispecific T-cell engagers (TCEs) as cancer therapeutics as well as considerations and potential strategies for designing the next generation TCE molecules.
Omid Vafa, Nathan D. Trinklein
doaj   +1 more source

Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy.

Blood
Bispecific antibodies (BsAb) that target CD3 and CD20 represent a new milestone in the treatment of patients with B-cell non-Hodgkin lymphoma. These drugs have demonstrated remarkable single-agent activity in heavily pretreated patients, and at least ...
J. Crombie, Tara Graff, L. Falchi, Yasmin H Karimi, R. Bannerji, L. Nastoupil, C. Thieblemont, R. Ursu, Nancy L. Bartlett, Victoria R. Nachar, Jonathan Weiss, Jane Osterson, K. Patel, Joshua D Brody, J. Abramson, M. Lunning, Nirav N Shah, Ayed Ayed, M. Kamdar, Benjamin M Parsons, P. Caimi, Ian W Flynn, A. Herrera, J. Sharman, Marshall Mckenna, Philippe Armand, Brad S. Kahl, Sonali M. Smith, A. Zelenetz, L. Budde, Martin Hutchings, T. Phillips, Michael J Dickinson   +32 more
semanticscholar   +1 more source

Analysis of off-tumour toxicities of T-cell-engaging bispecific antibodies via donor-matched intestinal organoids and tumouroids

Nature Biomedical Engineering, 2023
Predicting the toxicity of cancer immunotherapies preclinically is challenging because models of tumours and healthy organs do not typically fully recapitulate the expression of relevant human antigens.
Marius F. Harter, Timothy Recaldin, Régine Gérard, Blandine Avignon, Yannik Bollen, Cinzia Esposito, Karolina Guja-Jarosz, Kristina Kromer, Adrian M. Filip, Julien Aubert, A. Schneider, M. Bacac, Michael Bscheider, N. Stokar-Regenscheit, Salvatore Piscuoglio, Joep Beumer, N. Gjorevski   +16 more
semanticscholar   +1 more source

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors

OncoImmunology, 2018
We assessed the tolerability and antitumor activity of solitomab, a bispecific T-cell engager (BiTE®) antibody construct targeting epithelial cell adhesion molecule (EpCAM).
Maxim Kebenko, Marie-Elisabeth Goebeler, Martin Wolf, Annette Hasenburg, Ruth Seggewiss-Bernhardt, Barbara Ritter, Beate Rautenberg, Djordje Atanackovic, Andrea Kratzer, James B. Rottman, Matthias Friedrich, Eva Vieser, Stefanie Elm, Ingrid Patzak, Dorothea Wessiepe, Sabine Stienen, Walter Fiedler   +16 more
doaj   +1 more source

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies

Journal of Hematology & Oncology, 2021
Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities has become a promising strategy in clinical management of hematologic malignancies.
Z. Tian, Ming Liu, Ya Zhang, Xin Wang
semanticscholar   +1 more source

Advances in Therapy of Adult Patients with Acute Lymphoblastic Leukemia

Cells
The landscape of adult acute lymphoblastic leukemia (ALL) is dramatically changing. With very promising results seen with novel immunotherapeutics in the setting of relapsed and refractory disease, the prospect of using these agents in first-line therapy
Oscar Sucre, Saagar Pamulapati, Zeeshan Muzammil, Jacob Bitran   +3 more
doaj   +1 more source

The proximity of the N- and C- termini of bovine knob domains enable engineering of target specificity into polypeptide chains

mAbs, 2022
Cysteine-rich knob domains can be isolated from the ultralong heavy-chain complementarity-determining region (CDR) 3, which are unique to a subset of bovine antibodies, to create antibody fragments of ~4 kDa.
Alice Hawkins, Callum Joyce, Kevin Brady, Adam Hold, Alan Smith, Michael Knight, Conor Howard, Jean van den Elsen, Alastair D.G. Lawson, Alex Macpherson   +9 more
doaj   +1 more source